On October 13, GENFLEET-B fell 5.07% in regular trading, trading at HK$26.02, with turnover of HK$6.50 million. The decline followed a major shareholder reduction, and the company's buyback efforts have not fully absorbed the selling pressure.

According to disclosures, on September 24, Ourea Biotech HK Limited sold 6 million shares of GENFLEET-B at HK$27.30 per share, totaling approximately HK$163.8 million, reducing its stake to 4.64%. Meanwhile, although GENFLEET-B has been repurchasing H shares since September, including 135,000 shares for about HK$3.83 million on October 8, the cumulative buyback remains limited relative to the overhang from the reduction.

GENFLEET-B is a China-based innovative drug developer focused on oncology, autoimmune, and inflammatory diseases, with capabilities spanning target discovery, clinical development, and chemistry, manufacturing, and controls.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)